| Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, ... New England Journal of Medicine 369 (2), 134-144, 2013 | 4189 | 2013 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3086 | 2012 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2142 | 2018 |
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study EEW Cohen, D Soulières, C Le Tourneau, J Dinis, L Licitra, MJ Ahn, ... The Lancet 393 (10167), 156-167, 2019 | 1337 | 2019 |
| Combined nivolumab and ipilimumab in melanoma metastatic to the brain HA Tawbi, PA Forsyth, A Algazi, O Hamid, FS Hodi, SJ Moschos, ... New England Journal of Medicine 379 (8), 722-730, 2018 | 1168 | 2018 |
| Association of pembrolizumab with tumor response and survival among patients with advanced melanoma A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ... Jama 315 (15), 1600-1609, 2016 | 1093 | 2016 |
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ... The lancet oncology 13 (11), 1087-1095, 2012 | 1017 | 2012 |
| Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ... Immunity 49 (6), 1148-1161. e7, 2018 | 765 | 2018 |
| Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma AI Daud, K Loo, ML Pauli, R Sanchez-Rodriguez, PM Sandoval, ... The Journal of clinical investigation 126 (9), 3447-3452, 2016 | 530 | 2016 |
| The Hippo effector YAP promotes resistance to RAF-and MEK-targeted cancer therapies L Lin, AJ Sabnis, E Chan, V Olivas, L Cade, E Pazarentzos, S Asthana, ... Nature genetics 47 (3), 250-256, 2015 | 529 | 2015 |
| Intermodal selective attention. II. Effects of attentional load on processing of auditory and visual stimuli in central space K Alho, DL Woods, A Algazi, R Näätänen Electroencephalography and clinical Neurophysiology 82 (5), 356-368, 1992 | 468 | 1992 |
| Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC PC Tumeh, MD Hellmann, O Hamid, KK Tsai, KL Loo, MA Gubens, ... Cancer immunology research 5 (5), 417-424, 2017 | 443 | 2017 |
| Pembrolizumab cutaneous adverse events and their association with disease progression M Sanlorenzo, I Vujic, A Daud, A Algazi, M Gubens, SA Luna, K Lin, ... JAMA dermatology 151 (11), 1206-1212, 2015 | 431 | 2015 |
| Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ... Journal of Clinical Oncology 35 (36), 4050-4056, 2017 | 413 | 2017 |
| Lesions of frontal cortex diminish the auditory mismatch negativity K Alho, DL Woods, A Algazi, RT Knight, R Näätänen Electroencephalography and clinical neurophysiology 91 (5), 353-362, 1994 | 390 | 1994 |
| Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction G Moriceau, W Hugo, A Hong, H Shi, X Kong, CY Clarissa, RC Koya, ... Cancer cell 27 (2), 240-256, 2015 | 372 | 2015 |
| Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies AP Algazi, KK Tsai, AN Shoushtari, RR Munhoz, Z Eroglu, JM Piulats, ... Cancer 122 (21), 3344-3353, 2016 | 353 | 2016 |
| Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib GV Long, JS Weber, JR Infante, KB Kim, A Daud, R Gonzalez, JA Sosman, ... Journal of Clinical Oncology 34 (8), 871-878, 2016 | 331 | 2016 |
| High response rate to PD-1 blockade in desmoplastic melanomas Z Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ... Nature 553 (7688), 347-350, 2018 | 301 | 2018 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 289 | 2021 |
